TABLE 2

Comparison of clinical outcomes among patients treated continuously with DAP versus LZD and LZD versus LZD-to-DAP for VREF-BSI, after propensity score matchinga

OutcomeContinuous treatmentSequential treatment
DAP (n = 853)LZD (n = 853)Risk ratio (95% CI)P valueLZD (n = 217)LZD-to-DAP (n = 217)Risk ratio (95% CI)P value
30-day all-cause mortality [n (%)]251 (29.4)298 (34.9)1.13 (1.02–1.26)0.01575 (34.6)53 (24.4)1.29 (1.03–1.63)0.021
Infection-related mortalityb [n (%)]12 (1.4)46 (5.4)1.47 (1.19–2.09)<0.00116 (7.4)15 (6.9)1.04 (0.71–1.51)0.852
Hospital mortality [n (%)]250 (29.3)305 (35.8)1.16 (1.05–1.39)0.00488 (40.6)71 (32.7)1.19 (0.97–1.46)0.090
Persistent VREF-BSIc,d [n (%)]37 (6.4)54 (10.0)1.30 (1.02–1.67)0.02719 (10.3)8 (5.4)1.54 (0.85–2.80)0.107
Duration of VREF-BSI (days)d,e [median (IQR)]2 (1–3)3 (2–4)<0.0012 (1–5)2 (1–4)0.248
Hospital length of stay (days) [median (IQR)]21 (12–43)25 (14–47)0.00124 (14–51)22 (10–45)0.165
  • a Categorical variables were compared by using a chi-square or Fisher's exact test. Continuous variables were compared by using the Mann-Whitney U test. Propensity scores were derived from the following covariates: age ≥ 65 years, concomitant pneumonia, facility complexity level, infectious diseases consultation, source of VREF-BSI, previous VRE colonization, concomitant β-lactam treatment, intensive care unit admission, malignancy, solid organ transplant, Charlson comorbidity index, moderate to severe renal disease, severe liver disease, neutropenia, or thrombocytopenia.

  • b Death during treatment with DAP or LZD without microbiological clearance from bloodstream.

  • c Lack of microbiological clearance after ≥7 days.

  • d Comparison among those with at least 1 follow-up blood culture while on treatment (LZD [n = 539], DAP [n = 578]).

  • e Comparison among those with at least 1 follow-up blood culture while on treatment (LZD [n = 184], LZD-to-DAP [n = 147]).